News articles about MannKind Corporation (NASDAQ:MNKD) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MannKind Corporation earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.436567481881 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- MannKind Corp. breached its 50 day moving average in a Bearish Manner : MNKD-US : November 14, 2017 (finance.yahoo.com)
- Analyzing MannKind Corporation (MNKD) and Its Peers (americanbankingnews.com)
- Mannkind Corporation (NASDAQ:MNKD) Sees Price Swing – Down by 2.47% – First News 24 (firstnewspaper24.com)
- Does MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves Questions (finance.yahoo.com)
- MannKind Has Much Room for Upside in Diabetes Market: Here’s Why (finance.yahoo.com)
Shares of MannKind Corporation (NASDAQ:MNKD) opened at $3.11 on Wednesday. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.28 and a current ratio of 0.31. MannKind Corporation has a 1-year low of $0.67 and a 1-year high of $6.96.
MannKind Corporation (NASDAQ:MNKD) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.11). MannKind Corporation had a negative return on equity of 24.93% and a negative net margin of 155.83%. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.56 million. During the same quarter last year, the company earned $1.30 EPS. MannKind Corporation’s revenue for the quarter was down 98.7% compared to the same quarter last year. sell-side analysts anticipate that MannKind Corporation will post -1.13 EPS for the current year.
A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating on shares of MannKind Corporation in a research report on Tuesday, October 24th. Maxim Group reissued a “hold” rating on shares of MannKind Corporation in a research note on Wednesday, November 1st. Zacks Investment Research raised MannKind Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, ValuEngine lowered MannKind Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $0.92.
In other MannKind Corporation news, Director Kent Kresa acquired 166,600 shares of the company’s stock in a transaction dated Friday, October 13th. The shares were acquired at an average price of $6.00 per share, for a total transaction of $999,600.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.
MannKind Corporation Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.